Technology Licensing

TiVo and Xperi edge towards merger, and the creation of a $500 million licensing giant

The key questions that need to be answered as plans take shape to spin-off the combined IP businesses into a standalone company

TiVo and Xperi edge towards merger, and the creation of a $500 million licensing giant
19 Feb 2020

A deep dive into global innovation landscape emphasises the need for collaboration

Working together to develop new products is becoming a new business imperative, according to Clarivate’s latest top 100 global innovators report

19 Feb 2020

Huawei seeks to leverage invalidations in InterDigital dispute

The US-based licensing company faces an onslaught of invalidity actions at China's Patent Office, with about half of the decisions still to come

Latest

View all
18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

17 Feb 2020

PTAB decisions may derail Taiwan company’s litigation campaign 

ITRI spinoff CyWee has been “basically bankrupted by some of the largest companies in the world”, according to its counsel in an IPR case Read more

15 Feb 2020

The impact of Covid-19 will be felt across the global IP market

The race to patent a treatment for coronavirus in China is heating up, but its spread could be the story that affects every other story in tech this year Read more

14 Feb 2020

Five keys to successful technology licensing with the not-for-profit community

Huge amounts of innovation in the university and wider research worlds remain untapped but there are some clear tips to follow as companies search for new sources of value Read more

News

View all
8 Feb 2020

The inconvenient truth is that the West gifted China its 5G leadership

A lack of foresight and a complete absence of joined up thinking in both the US and Europe have handed Huawei and others huge advantages in a technology space that is set to change the world Read more

6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

5 Feb 2020

Wuhan lab says it will seek patent protection of Gilead antiviral

Application unlikely to succeed in light of Gilead's prior art, practitioners say. The pharmaceutical company is cooperating on clinical trials with Chinese partners Read more

1 Feb 2020

We need better thinking on US pharma patent reforms

As the presidential race heats up - and with even self-styled Democrat centrist Michael Bloomberg now promising radical regime change - life sciences IP professionals must interject some sanity into the debate Read more

Analysis

View all
13 Feb 2020

Slack the latest tech company to pick up former Yahoo! assets

As parent company winds itself up, Excalibur IP keeps doing deals - although big syndicated transaction remains elusive Read more

11 Feb 2020

Former Ford IP supremo Bill Coughlin on the end of the “age of unreasonableness” in auto

Speaking exclusively to IAM, the new CEO of law firm Harness Dickey advocates revisiting US royalty rate case law, while hailing a new Toyota licensing initiative as a big step   Read more

11 Feb 2020

Antitrust considerations now a much bigger factor in pharma patent dealmaking

Following recent forced divestments - and with growing political concern about life sciences acquisitions - the signs are that regulators will play a larger role in transactions Read more

10 Feb 2020

Gilead downplays Chinese lab’s coronavirus patent

“Too early to discuss” compulsory licensing of remdesivir, US company says as it continues clinical trials of antiviral in Wuhan Read more

Insights

View all
30 Jan 2019

Apple v Qualcomm is the global patent fight for our times

Why Qualcomm’s winning of an injunction in China against Apple is another sign that the patent market is drifting inexorably eastwards. With the country’s answer to the Court of Appeals for the Federal Circuit opening at the start of this year, rights holders have even more reason to turn to Chinese courts. Read more

30 Nov 2018

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative. Read more